WS12.02Dietary protein intake and overall diet quality in adults with cystic fibrosis following elexacaftor/tezacaftor/ivacaftor therapy

IF 5.4 2区医学 Q1 RESPIRATORY SYSTEM

Journal of Cystic Fibrosis Pub Date : 2025-06-01 DOI:10.1016/j.jcf.2025.03.559

L.R. Caley , P.T. Morgan , T.-J. Ellis , B. Smeuninx , L. Breen , L. Kinsey , O.W. Tomlinson , H. White , D.G. Peckham

{"title":"WS12.02Dietary protein intake and overall diet quality in adults with cystic fibrosis following elexacaftor/tezacaftor/ivacaftor therapy","authors":"L.R. Caley , P.T. Morgan , T.-J. Ellis , B. Smeuninx , L. Breen , L. Kinsey , O.W. Tomlinson , H. White , D.G. Peckham","doi":"10.1016/j.jcf.2025.03.559","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study characterised protein intake and diet quality in adults with cystic fibrosis (awCF), before and after elexacaftor/tezacaftor/ivacaftor (ETI), and compared to healthy controls, UK recommended dietary allowance (RDA, 0.75g·kg<sup>-1</sup>·day) and recommendations for those with elevated protein requirements and/or increased risk of sarcopenia (≥1.2g·kg<sup>−1</sup>·day<sup>−1</sup>).</div></div><div><h3>Methods</h3><div>As part of the Igloo-CF study, dietary intake was assessed in awCF at baseline (BL, n=40) and at >3 months post-ETI therapy (FUP, n=40), and healthy controls (CON, n=80) at a single time point. Each participant's protein intake, dose and distribution throughout the day relative to bodyweight, and overall diet quality was calculated.</div></div><div><h3>Results</h3><div>Mean age and BMI of awCF (at BL) and CON were 35.6 ± 9.8 years, 23.3±2.8kg·m<sup>-2</sup> and 37.7±14.6 years, 25.0±5.0kg·m-2 respectively, across both cohorts 52% were male. In awCF, median ppFEV<sub>1</sub> was 46.8 (IQR 34.8, 65.8) at BL and 56.5 (IQR 43.5, 72.6) at FUP, with time points a median of 68 weeks (range 20-94 weeks) apart, median duration of ETI at FUP 23 weeks (range 7-72 weeks). Both CON (1.39±0.47g·kg<sup>-1</sup>·day<sup>-1)</sup> and CF cohorts (BL: 1.44±0.52 g·kg<sup>-1</sup>·day<sup>-1),</sup> FUP: 1.12±0.32g·kg<sup>-1</sup>·day<sup>-1</sup>) had a higher mean daily protein intake than the current RDA for healthy adults. Daily protein intake decreased in CF participants at FUP, with levels below (≥1.2g·kg<sup>−1</sup>·day<sup>−1</sup>) recommendations for those with elevated protein requirements and/or at risk of sarcopenia (<em>P</em><0.05). Only 72% of awCF at BL and 64% of CON group met the recommended RDA on all measurement days. In the CF cohort, overall diet quality fell at FUP when on ETI therapy.</div></div><div><h3>Conclusion</h3><div>Adequate protein quality and quantity is essential to maintain skeletal muscle mass and function, particularly in catabolic states such as CF. This is particularly pertinent for a rapidly ageing population. More research on optimal protein requirements is needed to promote healthy ageing in awCF.</div><div><strong>Funded by:</strong> UK CF Trust (SRC 012)</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Pages S23-S24"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325006551","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This study characterised protein intake and diet quality in adults with cystic fibrosis (awCF), before and after elexacaftor/tezacaftor/ivacaftor (ETI), and compared to healthy controls, UK recommended dietary allowance (RDA, 0.75g·kg^-1·day) and recommendations for those with elevated protein requirements and/or increased risk of sarcopenia (≥1.2g·kg⁻¹·day⁻¹).

Methods

As part of the Igloo-CF study, dietary intake was assessed in awCF at baseline (BL, n=40) and at >3 months post-ETI therapy (FUP, n=40), and healthy controls (CON, n=80) at a single time point. Each participant's protein intake, dose and distribution throughout the day relative to bodyweight, and overall diet quality was calculated.

Results

Mean age and BMI of awCF (at BL) and CON were 35.6 ± 9.8 years, 23.3±2.8kg·m^-2 and 37.7±14.6 years, 25.0±5.0kg·m-2 respectively, across both cohorts 52% were male. In awCF, median ppFEV₁ was 46.8 (IQR 34.8, 65.8) at BL and 56.5 (IQR 43.5, 72.6) at FUP, with time points a median of 68 weeks (range 20-94 weeks) apart, median duration of ETI at FUP 23 weeks (range 7-72 weeks). Both CON (1.39±0.47g·kg^-1·day^-1) and CF cohorts (BL: 1.44±0.52 g·kg^-1·day^-1), FUP: 1.12±0.32g·kg^-1·day^-1) had a higher mean daily protein intake than the current RDA for healthy adults. Daily protein intake decreased in CF participants at FUP, with levels below (≥1.2g·kg⁻¹·day⁻¹) recommendations for those with elevated protein requirements and/or at risk of sarcopenia (P<0.05). Only 72% of awCF at BL and 64% of CON group met the recommended RDA on all measurement days. In the CF cohort, overall diet quality fell at FUP when on ETI therapy.

Conclusion

Adequate protein quality and quantity is essential to maintain skeletal muscle mass and function, particularly in catabolic states such as CF. This is particularly pertinent for a rapidly ageing population. More research on optimal protein requirements is needed to promote healthy ageing in awCF.

Funded by: UK CF Trust (SRC 012)

查看原文本刊更多论文

在elexaftor /tezacaftor/ivacaftor治疗后囊性纤维化成人患者的膳食蛋白质摄入量和总体饮食质量

目的：本研究描述了囊性纤维化（awCF）成人患者在使用elexaftor /tezacaftor/ivacaftor （ETI）前后的蛋白质摄入量和饮食质量，并与健康对照组相比，英国推荐的膳食摄入量（RDA， 0.75g·kg-1·天）和蛋白质需求升高和/或肌少症风险增加的患者的推荐摄入量（≥1.2g·kg -1·天）。方法作为Igloo-CF研究的一部分，在基线（BL, n=40）和eti治疗后3个月（FUP, n=40）以及健康对照组（CON, n=80）的单个时间点评估awCF患者的饮食摄入量。计算每个参与者的蛋白质摄入量、剂量和全天相对于体重的分布，以及总体饮食质量。结果awCF （BL）和CON的平均年龄和BMI分别为35.6±9.8岁（23.3±2.8kg·m-2）和37.7±14.6岁（25.0±5.0kg·m-2），男性占52%。在awCF中，BL组中位ppFEV1为46.8 (IQR为34.8,65.8)，FUP组中位ppFEV1为56.5 (IQR为43.5,72.6)，时间点间隔中位数为68周（范围20-94周），FUP组中位ETI持续时间为23周（范围7-72周）。CON组（1.39±0.47g·kg-1·day-1）和CF组（BL组：1.44±0.52 g·kg-1·day-1）和FUP组：1.12±0.32g·kg-1·day-1)的平均每日蛋白质摄入量均高于健康成人目前的RDA。在FUP时，CF参与者的每日蛋白质摄入量下降，对于蛋白质需求升高和/或有肌肉减少风险的参与者，建议蛋白质摄入量低于（≥1.2g·kg−1·day−1）（P<0.05）。在所有测量日，BL组只有72%的awCF和CON组64%的awCF达到推荐的RDA。在CF队列中，当接受ETI治疗时，总体饮食质量在FUP时下降。结论：充足的蛋白质质量和数量对于维持骨骼肌质量和功能至关重要，特别是在CF等分解代谢状态下，这对于快速老龄化的人口尤为重要。需要更多关于最佳蛋白质需求的研究来促进awCF的健康衰老。资助：UK CF Trust （SRC 012）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cystic Fibrosis 医学-呼吸系统

CiteScore

10.10

自引率

13.50%

发文量

1361

审稿时长

50 days

期刊介绍： The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.